News & Updates

In type 2 diabetes (T2D) patients with established heart failure (HF), use of alogliptin appears to contribute to an increased risk of HF exacerbation, reveals a study.

Remdesivir may cut the risk of symptoms and diagnoses associated with possible post-COVID conditions (PCC), otherwise known as long COVID.

Phase II data presented at CROI 2024 demonstrated the ability of an investigational, long-acting, oral once-weekly regimen comprising islatravir, a nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class capsid inhibitor, to maintain viral suppression at week 24 in virologically suppressed people living with HIV (PWH).